Schneider Electric calls for greater efforts to accelerate the energy transition and address the energy crisis: decarbonization and efficiency are key
- Call comes ahead of World Economic Forum annual meeting
- Schneider-commissioned research finds most companies planning to spend under 2% of revenues on sustainability and decarbonization initiatives
- On the demand side of the energy transition, only 31% of organizations currently push electrification as a way to decarbonize
Rueil-Malmaison (France), January 16, 2023 – Schneider Electric, the leader in the digital transformation of energy management and automation, today issued an urgent call for governments and companies around the world to accelerate their sustainability action and step up investments into technologies that will help them reduce their carbon emissions and bolster their energy security.
The call comes amid spiking energy prices, an energy supply crisis and fast accelerating climate change, which together pose major challenges for companies, economies and societies around the globe. These challenges form the backdrop for the World Economic Forum’s annual meeting in Davos, Switzerland, from 16-20 January, which senior Schneider Electric executives will attend.
"Today’s climate and energy crises are an economic reality for ever-increasing numbers of people. As business leaders and policymakers come together at Davos, we must act in our own best long-term, not short-term, interests," said Jean-Pascal Tricoire, Schneider Electric’s Chairman and CEO. “We must not avoid the tough decisions.There can be no long-term prosperity without a complete energy transition. At Schneider, our approach is to ‘Digitize Strategize, Decarbonize’ - businesses, governments and societies must do this now, to make good on the commitments they have made."
With 38% of global CO2 emissions coming from the built environment, and a further 32% from industry1, Schneider Electric’s products, software and services in the areas of industrial automation and energy management help companies, industries, building managers and households to decarbonize and digitize their energy usage. Schneider Electric also offers deep insights into decarbonization trends and solutions, through surveys, research and in-depth reports compiled by the Schneider Electric Sustainability Research Institute.
An independent survey of more than 500 C-suite executives commissioned by Schneider last year found that corporate sustainability commitments and investments are often hampered by the complexity of decarbonization. On average, the financial commitment to sustainability and decarbonization initiatives across the companies surveyed was less than 2% of projected revenue over the next three years - despite the fact such investments are often efficient and cost-effective, with return on investment often under one to three years.
Respondents highlighted stakeholder alignment, budget, technology, skills and regulation as challenges to sustainability implementation. However, a majority noted that enhanced industrial automation and the upgrading of electrical infrastructure will form a key part of their sustainability plan for the next three years.
Renewable energy procurement is among the top initiatives pursued on the supply side, while electrification – a key demand-side measure – scores low among organizations’ sustainability priorities. Alongside electrification, delivering increased efficiency across existing infrastructure through digitization and automation will be among the most important levers in the next decade, being the fastest and most capital-efficient means for many organizations to reduce emissions.
Embracing sustainability as a business imperative, with digital solutions key to navigating the global energy crisis
A further recent Schneider Electric report on the EU’s electrification potential found that focusing on sectors in which electrification is both feasible and attractive could raise electricity’s share of the energy mix from around 20% to 50%. In turn, the share of natural gas and oil would drop by around 50%, contributing significantly to improved energy security. Schneider Electric offers specific, practical solutions to help companies navigate this transition more quickly and efficiently.
Schneider Electric points out that today’s European energy crisis follows decades of secure, reliably available energy and relatively stable pricing. Many are experiencing for the first time unpredictable energy supplies and unaffordable prices, demonstrating a failure both of long-term energy security preparedness, and of the implementation of decarbonization plans. This in turn underscores the importance of reevaluating the entire energy equation, from the supply side (energy transition) to the demand side (energy efficiency).
“Purpose and profits must align to become powerful forces in the fight against climate change,” said Mr. Tricoire. “We already have the technology to avert the energy and climate crises, and to deliver safe, reliable, and sustainable energy distribution and energy use. Our data-driven approach, spanning industrial automation, digitization and the digital twin technology of the enterprise metaverse, combines to unlock a brighter, more sustainable and more prosperous future. The urgency for action has never been greater than it is now.”
About Schneider Electric
Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.
Our mission is to be your digital partner for Sustainability and Efficiency.
We drive digital transformation by integrating world-leading process and energy technologies, end-point to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.
We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)11.12.2023 07:15:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1; the safety profile of iptacopan was consistent with previously reported data1-3 C3 glomerulopathy (C3G) is an ultra-rare complement-mediated kidney disease, with approximately 50% of patients progressing to kidney failure within 10 years of diagnosis4-7; currently no treatments address the underlying cause of C3G7-9 Novartis plans to review results with global health authorities to enable potential submissions in 2024; data will be submitted for presentation at an upcoming medical meeting Iptacopan demonstrated positive Phase III results in IgA nephropathy (IgAN) at the interim analysis and a late-stage development program is ongoing across four investigational indications10-14 Basel, December 11, 2023 — Novartis today announced positive topline results from the six-month, double-blind period
Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs11.12.2023 07:00:00 CET | Press release
Press Release Nokia and BT Group sign agreement to drive new 5G monetization opportunities through telco APIs Memorandum of understanding covers the utilization of Nokia’s Network as Code platform and developer portal with BT Group’s cloud-native network 11 December 2023 Espoo, Finland – Nokia and BT Group today announced an agreement to develop new 5G network monetization opportunities through Nokia’s Network as Code platform with developer portal (platform) and BT Group’s cloud-native network. BT Group, which operates EE – the UK’s best mobile network1 – is, like other communications service providers, looking to Nokia’s growing ecosystem of developer partners to gain access to simplified network capabilities in the form of software code that can be built into applications for enterprise, industrial, and consumer use cases. The Nokia platform helps operators monetize their 5G network assets beyond pure connectivity. It provides application developers with tools such as Software Devel
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma11.12.2023 07:00:00 CET | Press release
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6 Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, 9-12 December 2023. Based on 32-month and 3-year follow-ups of two pivotal studies for fixed-duration treatments of Columvi® (glofitamab) and Lunsumio® (mosunetuzumab), respectively, data show that remissions were maintained in the majority of patients with heavily pre-treated lymphomas.1,2 Additionally, new early-phase data of novel Columvi or Lunsumio combination regimens support o
Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone11.12.2023 01:30:59 CET | Press release
Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone Phase 3 data showed Sarclisa added to carfilzomib, lenalidomide and dexamethasone (KRd) in patients with newly diagnosed, transplant-eligible multiple myeloma resulted in 77% of patients achieving minimal residual disease (MRD) negativity after consolidation therapy, detected with a sensitivity of 10-5MRD negativity rate measured at a sensitivity of 10-6 was 67% for Sarclisa combination therapyResults shared during oral presentation at ASH 2023 plenary scientific session PARIS, December 10, 2023. The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidatio